Skip to main navigation PRESS RELEASES Investors Overview Press Releases Events & Presentations Stock Information Analyst Coverage SEC Filings Corporate Governance Email Alerts Contact IR FAQ Year 2021 C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results – Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63 rd ASH Annual Meeting – – Investigational New Drug (IND) Application for CFT8634, a Degrader Targeting BRD9 for the Treatment of Synovial Sarcoma READ MORE NOV 10, 2021 C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results – Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 – – Received Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma – – Initiated Investigational New Drug (IND)-Enabling Activities for READ MORE AUG 11, 2021 C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. READ MORE AUG 11, 2021 C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the closing of an READ MORE JUN 21, 2021 C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma – CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin’s Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins – – CFT7455 Resulted in Improved Efficacy and Potency in Tumor Xenograft Models Compared to Investigational and Approved READ MORE JUN 21, 2021 C4 Therapeutics Announces Pricing of Public Offering WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the pricing of an READ MORE JUN 16, 2021 C4 Therapeutics Launches Proposed Public Offering WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that it has launched a READ MORE JUN 14, 2021 C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies – CFT7455 is Company’s First Program to Advance to Clinic – WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins READ MORE JUN 14, 2021 C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation – CFT8919 Induces Tumor Regression in Pre-clinical Models Resistant to First- and Third-generation EGFR Inhibitors – – CFT8919 Demonstrates Intracranial Activity Pre-clinically, Indicating the Potential to be Effective Against CNS Metastases – – Pre-clinical Data Support Plans to Advance CFT8919 to READ MORE JUN 7, 2021 C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies – IND Submission for CFT8919 Anticipated mid-2022; Phase 1/2 Trial Initiation Expected by YE 2022 – – CFT8919 is Potent and Mutant-Selective BiDAC T M Degrader of EGFR L858R for the Treatment of Non-Small Cell Lung Cancer – – CFT8919 Pre-clinical Data on EGFR L858R-driven NSCLC to be Presented at READ MORE MAY 26, 2021 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 21 Toolkit Phone 617-231-0700 Location 490 Arsenal Way, Suite 200 Watertown, MA 02472 Email info@c4therapeutics.com © 2021 C4 Therapeutics, Inc. Privacy Policy Terms of Use Agreement Sitemap